Discover investment opportunities in Top Genomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Genomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Genomics Stocks using our Smart AI Filter.
9 stocks found for "Top Genomics Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.77 | ±71.4% | -18.6 | 0.00% | |||
3.05 | ±100.0% | -2.4 | 0.00% | |||
2.51 | ±100.0% | -1.1 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.19 | ±53.7% | -156.9 | 0.00% | |||
1.82 | ±67.7% | -15.1 | 0.00% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.89 | ±41.9% | 22.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What sector-specific opportunities exist for genomics stocks like ILMN and CRSP?
A: Genomics stocks, such as ILMN (Illumina) and CRSP (CRISPR Therapeutics), benefit from the growing demand for personalized medicine and advances in genetic research. These companies often engage in innovative solutions, potentially leading to breakthrough therapies and diagnostics.
Q: How do NVTA and EDIT typically perform in volatile markets?
A: NVTA (Invitae) and EDIT (Editas Medicine) can experience high volatility due to their involvement in emerging biotech technologies. Market sentiment on regulatory progress and scientific milestones often influences their stock performance more than broader economic conditions.
Q: Are companies like NTLA and PACB attractive for long-term growth investors?
A: Long-term growth investors may find NTLA (Intellia Therapeutics) and PACB (Pacific Biosciences) appealing due to their cutting-edge genetic editing and sequencing technologies. Continued advancements in these fields could underpin sustained growth potential.
Q: Can VERV and BEAM be considered for ESG-focused portfolios?
A: VERV (Verve Therapeutics) and BEAM (Beam Therapeutics) might align with ESG portfolios as they focus on ethical gene-editing technologies aimed at addressing serious health conditions. However, investors should assess individual company ESG practices and impacts.
Q: What risks should investors consider when investing in TWST and DNA?
A: TWST (Twist Bioscience) and DNA (Ginkgo Bioworks) face risks including scientific and regulatory hurdles, as well as competition in the synthetic biology field. Investors should consider the potential for market disruptions and innovation failures.
Q: Do any genomics stocks pay dividends?
A: Most genomics stocks like ILMN, NVTA, or CRSP typically do not pay dividends. Companies in this industry often reinvest earnings into research and development to fuel growth, rather than returning capital to shareholders.